:: Library Catalog

Image de couverture de livre

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Sophie E. Claudel, Donald M. Lloyd‐Jones, Sushrut S. Waikar, Ashish Verma
Format:	Artículo Open Access
Publié:	Wiley 2026
Sujets:	Diabetes, Obesity and Metabolism
Accès en ligne:	https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.70607
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Prevalence of Cardiovascular‐Kidney‐Metabolic Conditions Across Body Mass Index Categories: The Distinct Burden of Severe (Class III ) Obesity
par: Saif S. Rathore, et autres
Publié: (2026)

Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome
par: Evan Zeitler, et autres
Publié: (2026)

The Evolving Role of High‐Sensitivity C‐Reactive Protein for Mortality Prediction Across the Spectrum of Cardiovascular–Kidney–Metabolic Syndrome
par: Jing Li, et autres
Publié: (2026)

Diabetic kidney disease, biomarkers, and finerenone
par: Ashish Verma, et autres
Publié: (2026)

Proteomic Profiling Captures Residual Cardiovascular Risk Beyond the PREVENT Model in Individuals With Cardiovascular–Kidney–Metabolic Syndrome Stages 2–3
par: Xuefei Han, et autres
Publié: (2026)

Association of Physical Activity With All‐Cause and CVD Mortality Across Metabolic and Obesity Phenotypes
par: Yunmin Han, et autres
Publié: (2026)

A Physiological Model of Incretin‐Based Therapies and Hierarchical Energy Allocation Across Metabolic Phenotypes
par: Christine Stier, et autres
Publié: (2026)

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
par: Michelantonio De Fano, et autres
Publié: (2026)

Intrapancreatic Fat Deposition and Metabolic Signatures Across Adiposity Phenotypes in Chinese Adults: A Computed Tomography Analysis
par: Wenlu Zong, et autres
Publié: (2026)

Enriched Metabolic Phenotyping Refines Phenotypic Resolution of Type 2 Diabetes
par: Min Wang, et autres
Publié: (2026)

Concurrence of the Core Mechanistic Tenets of the American Heart Association Statement on the Cardiovascular–Kidney–Metabolic Syndrome and the Adipokine Hypothesis of Heart Failure With Preserved Ejection Fraction
par: Milton Packer
Publié: (2026)

Cardiovascular Disease Risk Prediction in Patients With Metabolic Dysfunction‐Associated Steatohepatitis
par: Joe Hollinghurst, et autres
Publié: (2026)

Association of Cardiovascular‐Kidney‐Syndrome and Brain Macrostructure and Microstructure Injury: A Prospective Cohort Study
par: Guanyu Niu, et autres
Publié: (2026)

Correction to “Association of Cardiovascular‐Kidney‐Syndrome and Brain Macrostructure and Microstructure Injury: A Prospective Cohort Study”
Publié: (2026)

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses
par: David Z. I. Cherney, et autres
Publié: (2026)

Serum IGF ‐1 and the Risk of Cardio‐Kidney Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease
par: Yongin Cho, et autres
Publié: (2026)

High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics
par: Srilaxmi Kalavalapalli, et autres
Publié: (2026)

Sex‐Specific Associations of Inflammatory Biomarkers With All‐Cause and Cardiovascular Mortality Across Glycaemic Status: A Prospective UK Biobank Study
par: Yawen Zhang, et autres
Publié: (2026)

The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk
par: Elias John Elenjickal, et autres
Publié: (2026)

Pathways between race, structural racism, and obesity across census tracts in the United States
par: Leonard E. Egede, et autres
Publié: (2026)

Cost‐Effectiveness of Control‐ IQ + Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States
par: Neda Al Rawashdh, et autres
Publié: (2026)

Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease
par: Masaru Matsui, et autres
Publié: (2026)

Dose–Response Effect of Glucagon on Glucose, Beta‐Cell Secretion and Metabolism in Healthy Individuals
par: Sophie Betty Brock, et autres
Publié: (2026)

Kidney Effects of Finerenone Added to Sodium‐Glucose Cotransporter 2 Inhibitors in Patients With Diabetic Kidney Disease
par: Qing Yang, et autres
Publié: (2026)

Semaglutide and Cardiovascular Outcomes According to Baseline Aspirin Use: Analyses of the SOUL and SELECT Trials
par: Dirk Müller‐Wieland, et autres
Publié: (2026)

The impact of overweight and obesity on health outcomes in the United States from 1990 to 2021
par: Omar Al Ta'ani, et autres
Publié: (2024)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
par: Yunwen Xu, et autres
Publié: (2025)

Supporting Weight Management for Kidney Transplant Candidates in People With Obesity on Haemodialysis: The First National Survey of UK Kidney Healthcare Providers
par: Adrian Brown, et autres
Publié: (2026)

Disparities in heart failure deaths among people with diabetes in the United States: 1999–2020
par: Benjamin Grobman, et autres
Publié: (2025)

Regional disparities in type 2 diabetes prevalence and associated risk factors in the United States
par: Sulakshan Neupane, et autres
Publié: (2024)

Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk
par: Peter Rossing, et autres
Publié: (2024)

Diabetes, Obesity and Metabolism
Publié: (2026)

Diabetes, Obesity and Metabolism
Publié: (2026)

Diabetes, Obesity and Metabolism
Publié: (2026)

Diabetes, Obesity and Metabolism
Publié: (2024)

Diabetes, Obesity and Metabolism
Publié: (2024)

Diabetes, Obesity and Metabolism
Publié: (2025)

Diabetes, Obesity and Metabolism
Publié: (2024)

Diabetes, Obesity and Metabolism
Publié: (2024)

Diabetes, Obesity and Metabolism
Publié: (2024)